"Both primary percutaneous coronary intervention and fibrinolysis are well-recognized treatments for STEMI in international guidelines, and benefits are maximized when treatment occurs early," according to background information in the article. STEMI (ST-segment elevation myocardial infarction) is a certain pattern on an electrocardiogram following a heart attack. "However, randomized trials and selective registries are limited in their ability to assess the effect of timeliness of reperfusion on outcomes in real-world STEMI patients."

Laurie Lambert, Ph.D., of the Que­bec Healthcare Assessment Agency, Montreal, Canada, and colleagues conducted a province-wide evaluation of STEMI care in Que­bec (population, 7.8 million) to determine the use of reperfusion treatments (such as PPCI or fibrinolysis) and their delays and whether STEMI reperfusion treatment outside of the guideline-recommended delays was associated with poorer outcomes than treatment within recommended delays. The researchers analyzed data of STEMI care for 6 months during 2006-2007 in 80 hospitals in Quebec. Maximum delays rec­ommended in international guidelines for PPCI are 90 minutes; 30 minutes for fibrinolysis.

Of the patients treated with acute reperfusion (n = 1,832), 78.6 percent (1,440) underwent PPCI and 21.4 percent (392) received fibrinolytic therapy. Among patients who underwent PPCI, the median (midpoint) door-to-balloon time was 110 minutes. PPCI was untimely (greater than 90 minutes) in 68 percent of patients. For patients who received fibrinolysis, the median delay was 33 minutes, and untimely (greater than 30 minutes) in 54 percent of patients. Incidence of the combined outcome (death or readmission for heart failure or heart attack) at 1 year was 13.5 percent for fibrinoly­sis patients and 13.6 percent for PPCI patients.

"When the 2 treatment groups were combined, patients treated outside of recommended delays had an adjusted higher risk of death at 30 days (6.6 percent vs. 3.3 percent) and a statistically nonsignificant increase in risk of death at 1 year (9.3 percent vs. 5.2 percent) compared with patients who received timely treat­ment. Patients treated outside of recommended delays also had an adjusted higher risk for the combined outcome of death or hospital readmission for congestive heart failure or acute myocardial infarction [heart attack] at 1 year (15.0 percent vs. 9.2 percent). At the regional level, after adjustment, each 10 percent increase in patients treated within the recommended time was associated with a decrease in the region-level odds of overall 30-day mortality," the authors write.

"Our study, while consistent with reg­istry and clinical data associating longer treatment delays with poorer out­comes, is novel and robust in several ways. Above all, it represents not a sam­pling but more than 95 percent of all STEMI patients within a large and complex sys­tem of care and provides very recent information that transcends the rela­tive selectivity of randomized clinical trials and most registries."

" … we believe this evaluation repre­sents a needed contribution to the evi­dence base for deriving clinical practice guidelines and an important advance in knowledge of the outcomes associated with contemporary processes of STEMI care. This 'real-world' information is rel­evant both clinically and from a perspec­tive of evidence-based health care policy and planning, pointing to the lifesaving potential for approaches that focus on offering the most timely reperfusion treatment to patients with STEMI," the researchers write.

They add that time, rather than mode of reperfu­sion, emerges as a critical determinant of outcome in this systematic evalua­tion of STEMI care. "Regardless of reper­fusion strategy, patients treated be­yond maximum recommended delays had increased mortality."

Note: If no author is given, the source is cited instead.

• Heart Disease
• Wounds and Healing
• Today's Healthcare
• Stroke Prevention
• Diseases and Conditions
• Multiple Sclerosis Research

• Ischaemic heart disease
• Coronary heart disease
• COX-2 inhibitor
• Low density lipoprotein
• Cardiac arrest
• High density lipoprotein